Ustekinumab biosimilar (Bio-Thera)

乌司奴单抗生物类似药（百奥泰）

Report date: 2026/05/21 20:00:22

Base Information

Drug NameUstekinumab biosimilar (Bio-Thera)
Drug Alias Nameustekinumab-hmnySTARJEMZAUsymro艾沙力喜沙立 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-12 subunit beta inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-12 subunit betaInterleukin-23
Therapy Area/IndicationsPlaque psoriasisAutoimmune DiseasesPsoriasis +[6] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Approved Indications in ChinaPlaque psoriasisCrohn Disease
Original Approved Country/TerritoryUnited States
Original Approved Date2025/05/22
Country/TerritoryBulgariaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPharmaparkBio-Thera Solutions LtdHikma Pharmaceuticals +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A